WallStreetZenWallStreetZen

NASDAQ: SCTX
Scribe Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SCTX

Based on 4 analysts offering 12 month price targets for Scribe Therapeutics Inc

Min Forecast
$37.00+25.76%
Avg Forecast
$51.75+75.9%
Max Forecast
$60.00+103.94%

Should I buy or sell SCTX stock?

Based on 4 analysts offering ratings for Scribe Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SCTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SCTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their SCTX stock forecasts and price targets.

SCTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-03
lockedlocked$00.00+00.00%2026-08-18
lockedlocked$00.00+00.00%2026-08-18
lockedlocked$00.00+00.00%2026-08-18

1 of 1

Forecast return on equity

Is SCTX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is SCTX forecast to generate an efficient return on assets?

Company
-142.23%
Industry
-4.93%
SCTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SCTX earnings per share forecast

What is SCTX's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$5.56
Avg 2 year Forecast
-$4.19
Avg 3 year Forecast
-$4.35

SCTX revenue forecast

What is SCTX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$12.1M
Avg 2 year Forecast
$6.9M
Avg 3 year Forecast
$7.1M

SCTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SCTX$29.42$51.75+75.90%Strong Buy
CTNM$14.82$19.50+31.58%Buy
ARVN$8.40$16.29+93.88%Strong Buy
PROK$1.81$12.00+562.98%Buy
RGNX$8.69$17.67+103.30%Buy
View Top Biotech Stocks

Scribe Therapeutics Stock Forecast FAQ

Is Scribe Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: SCTX) stock is to Strong Buy SCTX stock.

Out of 4 analysts, 2 (50%) are recommending SCTX as a Strong Buy, 2 (50%) are recommending SCTX as a Buy, 0 (0%) are recommending SCTX as a Hold, 0 (0%) are recommending SCTX as a Sell, and 0 (0%) are recommending SCTX as a Strong Sell.

If you're new to stock investing, here's how to buy Scribe Therapeutics stock.

What is SCTX's earnings growth forecast for 2026-2028?

(NASDAQ: SCTX) Scribe Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.77%.

Scribe Therapeutics's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast SCTX's earnings for 2026 to be -$105,241,209, with the lowest SCTX earnings forecast at -$132,654,282, and the highest SCTX earnings forecast at -$77,724,012. On average, 6 Wall Street analysts forecast SCTX's earnings for 2027 to be -$79,268,837, with the lowest SCTX earnings forecast at -$112,988,053, and the highest SCTX earnings forecast at -$55,659,139.

In 2028, SCTX is forecast to generate -$82,390,671 in earnings, with the lowest earnings forecast at -$115,399,949 and the highest earnings forecast at -$63,212,880.

What is SCTX's revenue growth forecast for 2026-2028?

(NASDAQ: SCTX) Scribe Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 47.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.89%.

Scribe Therapeutics's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast SCTX's revenue for 2026 to be $229,262,645, with the lowest SCTX revenue forecast at $74,212,186, and the highest SCTX revenue forecast at $518,633,374. On average, 6 Wall Street analysts forecast SCTX's revenue for 2027 to be $130,098,505, with the lowest SCTX revenue forecast at $0, and the highest SCTX revenue forecast at $217,676,457.

In 2028, SCTX is forecast to generate $135,115,400 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $238,539,168.

What is SCTX's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: SCTX) forecast ROA is -142.23%, which is lower than the forecast US Biotechnology industry average of -4.93%.

What is SCTX's Price Target?

According to 4 Wall Street analysts that have issued a 1 year SCTX price target, the average SCTX price target is $51.75, with the highest SCTX stock price forecast at $60.00 and the lowest SCTX stock price forecast at $37.00.

On average, Wall Street analysts predict that Scribe Therapeutics's share price could reach $51.75 by Sep 3, 2027. The average Scribe Therapeutics stock price prediction forecasts a potential upside of 75.9% from the current SCTX share price of $29.42.

What is SCTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SCTX) Scribe Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that SCTX's EPS will be -$5.56 for 2026, with the lowest EPS forecast at -$7.01, and the highest EPS forecast at -$4.11. On average, analysts forecast that SCTX's EPS will be -$4.19 for 2027, with the lowest EPS forecast at -$5.97, and the highest EPS forecast at -$2.94. In 2028, SCTX's EPS is forecast to hit -$4.35 (min: -$6.10, max: -$3.34).

What is SCTX's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: SCTX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.